Molecular Hydrogen Capsule Therapy for Primary Biliary Cholangitis With Elevated IgG4: A Case Report on Immune Marker Normalization

YUN-TING LIN; JENG-WEI LU; JUNG-CHUN LIN; YI-JUNG HO; SHAN-WEN LUI; TING-YU HSIEH; HSIAO-CHEN LIU; KUANG-YIH WANG; FENG-CHENG LIU

doi:10.21873/invivo.13968

Article Figures & Data

Figures

Download figure
Open in new tab
Download powerpoint
Figure 1.
Changes in serum levels of aspartate transaminase (AST) and alanine aminotransferase (ALT) before (August 27, 2024) and after the initiation of molecular hydrogen therapy. Both AST and ALT levels exhibited decreasing trends following the commencement of molecular hydrogen therapy on August 30, 2024.
Download figure
Open in new tab
Download powerpoint
Figure 2.
Immunophenotypic changes of B cells following molecular hydrogen therapy. Whole blood analysis was conducted before and after molecular hydrogen therapy with the Health Control (HC) group shown for comparison (far left). Panels (A, B, and E) show that naïve B cell PD-1+, total B cell PD-1+, and regulatory B cell (Breg) populations significantly increased after molecular hydrogen therapy, surpassing the levels observed in the HC group. Panels (C, D, and F) demonstrate stable conditions for switched memory (SM) B cell Fas+, SM B cell CD21+, and naïve B cell HLADR+ populations following therapy.
Download figure
Open in new tab
Download powerpoint
Figure 3.
Immunophenotypic changes of T cells following molecular hydrogen therapy. Whole blood analysis was conducted before and after molecular hydrogen therapy, with the Health Control (HC) group shown for comparison (far left). Panels (A, B, C, D, E, and F) show that the percentage of effector memory (EM) cytotoxic T cells (Tc) Tim-3+, effector helper T cells (Th) KLRG1+, effector Tc Tim-3+, EM Tc KLRG1+, EM Th Tim-3+, and effector Tc KLRG1+ increased following molecular hydrogen therapy, eventually returning to levels comparable to those in the HC group.